NO923911L - Nye 17beta-substituerte aza-androstan derivater - Google Patents

Nye 17beta-substituerte aza-androstan derivater

Info

Publication number
NO923911L
NO923911L NO92923911A NO923911A NO923911L NO 923911 L NO923911 L NO 923911L NO 92923911 A NO92923911 A NO 92923911A NO 923911 A NO923911 A NO 923911A NO 923911 L NO923911 L NO 923911L
Authority
NO
Norway
Prior art keywords
17beta
new
phe
formula
group
Prior art date
Application number
NO92923911A
Other languages
English (en)
Norwegian (no)
Other versions
NO923911D0 (no
Inventor
Michel Biollaz
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of NO923911D0 publication Critical patent/NO923911D0/no
Publication of NO923911L publication Critical patent/NO923911L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
    • C07J73/001—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom
    • C07J73/005—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom by nitrogen as hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO92923911A 1991-10-09 1992-10-08 Nye 17beta-substituerte aza-androstan derivater NO923911L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH297891 1991-10-09

Publications (2)

Publication Number Publication Date
NO923911D0 NO923911D0 (no) 1992-10-08
NO923911L true NO923911L (no) 1993-04-13

Family

ID=4245915

Family Applications (1)

Application Number Title Priority Date Filing Date
NO92923911A NO923911L (no) 1991-10-09 1992-10-08 Nye 17beta-substituerte aza-androstan derivater

Country Status (19)

Country Link
US (2) US5304562A (enExample)
EP (1) EP0538192B1 (enExample)
JP (1) JPH05213989A (enExample)
KR (1) KR930007969A (enExample)
AT (1) ATE152121T1 (enExample)
AU (1) AU657579B2 (enExample)
CA (1) CA2080054A1 (enExample)
DE (1) DE59208383D1 (enExample)
DK (1) DK0538192T3 (enExample)
ES (1) ES2101073T3 (enExample)
FI (1) FI924529A7 (enExample)
GR (1) GR3024013T3 (enExample)
HU (1) HUT62600A (enExample)
IL (1) IL103361A (enExample)
MX (1) MX9205792A (enExample)
NO (1) NO923911L (enExample)
NZ (1) NZ244640A (enExample)
TW (1) TW263513B (enExample)
ZA (1) ZA927747B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304562A (en) * 1991-10-09 1994-04-19 Ciba-Geigy Corporation 17β-substituted Aza-androstane derivatives
WO1993023039A1 (en) * 1992-05-20 1993-11-25 Merck & Co., Inc. Substituted 4-aza-5a-androstan-ones as 5a-reductase inhibitors
SK137994A3 (en) * 1992-05-20 1995-04-12 Merck & Co Inc 7-beta-substituted-4-aza-5-alpha-cholestan-ons their using for production of pharmaceutical agent and pharmaceutical agent containing them
GB9210880D0 (en) * 1992-05-21 1992-07-08 Smithkline Beecham Corp Compounds
GB9216284D0 (en) * 1992-07-31 1992-09-16 Erba Carlo Spa Fluorinated 17beta-substituted 4-aza-5alpha-androstane-3-one derivatives
HU212459B (en) * 1992-10-02 1996-06-28 Richter Gedeon Vegyeszet Process for producing new 17-beta-substituted 4-aza-androstane-derivatives and pharmaceutical compositions containing them
DE69329933T2 (de) * 1992-10-06 2001-07-19 Merck & Co., Inc. 17-beta-carboxanilid derivate von 4-aza-5-alpha-androstan-3-one als 5-alpha-reduktase-hemmende arzneimittel
TW369521B (en) * 1993-09-17 1999-09-11 Smithkline Beecham Corp Androstenone derivative
TW408127B (en) * 1993-09-17 2000-10-11 Glaxo Inc Androstenones
US5470976A (en) * 1994-09-07 1995-11-28 Merck & Co., Inc. Process for the stereoselective reduction of steroid enelactams
US5543417A (en) * 1994-10-21 1996-08-06 Merck & Co., Inc. Combination method of treating acne using 4-AZA-5α-cholestan-ones and 4-AZA-5α-androstan-ones as selective 5α-reductase inhibitors with anti-bacterial, keratolytic, or anti-inflammatory agents
US5595996A (en) * 1994-10-25 1997-01-21 Merck & Co., Inc. 7-substituted 4-aza cholanic acid derivatives and their use
US5656613A (en) * 1995-01-04 1997-08-12 Merck & Co., Inc. Treatment of hyperandrogenic conditions
JPH11512434A (ja) * 1995-09-15 1999-10-26 メルク エンド カンパニー インコーポレーテッド アンドロゲン過剰状態治療用の４−アザステロイド
USRE39056E1 (en) * 1995-09-15 2006-04-04 Merck & Co, Inc. 4-Azasteroids for treatment of hyperandrogenic conditions
US5998427A (en) * 1998-05-14 1999-12-07 Glaxo Wellcome Inc. Androstenones
US6645974B2 (en) 2001-07-31 2003-11-11 Merck & Co., Inc. Androgen receptor modulators and methods for use thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4377584A (en) * 1978-04-13 1983-03-22 Merck & Co., Inc. 4-Aza-17β-substituted-5α-androstan-3-one-reductase inhibitors
US5049562A (en) * 1984-02-27 1991-09-17 Merck & Co., Inc. 17β-acyl-4-aza-5α-androst-1-ene-3-ones as 5α-reductase inhibitors
NZ211145A (en) * 1984-02-27 1988-10-28 Merck & Co Inc 4-aza-5-alpha-androst-1-en-3-ones and pharmaceutical compositions
US4760071A (en) * 1984-02-27 1988-07-26 Merck & Co., Inc. 17β-N-monosubstituted carbamoyl-4-aza-5α-androst-1-en-3-ones which are active as testosterone 5α-reductase inhibitors
GB8505862D0 (en) * 1985-03-07 1985-04-11 Erba Farmitalia Steroidic 5alpha-reductase inhibitors
US4845104A (en) * 1986-11-20 1989-07-04 Merck & Co., Inc. Oxidized analogs of 17β-N-monosubstituted-carbamoyl-4-aza-5-α-androstan-3-ones
EP0271219B1 (en) * 1986-11-20 1992-07-29 Merck & Co. Inc. Topical pharmaceutical composition containing 17-beta-methoxycarbonyl-4-methyl-4-aza-5-alpha-androst-1-en-3-one
US4888336A (en) * 1987-01-28 1989-12-19 Smithkline Beckman Corporation Steroid 5-alpha-reductase inhibitors
EP0285383B1 (en) * 1987-04-03 1994-03-16 Merck & Co. Inc. Treatment of prostatic carcinoma with 17beta-n-monosubstituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones
US5237061A (en) * 1988-10-31 1993-08-17 Merck & Co., Inc. Methods of synthesizing benign prostatic hypertropic agents and their intermediates
AU5856090A (en) * 1989-07-07 1991-02-06 Endorecherche Inc. Androgen derivatives for use in the inhibition of sex steroid activity
CA2023157A1 (en) * 1989-08-21 1991-02-22 Gary H. Rasmusson 17 beta-acyl-4-aza-5 alpha-androst-1-ene-3-ones as 5 alpha-reductase inhibitors
US5120847A (en) * 1990-08-27 1992-06-09 Merck & Co., Inc. Process for iodinating or brominating the α-methylenic carbon of a secondary amide
IE76452B1 (en) * 1990-10-29 1997-10-22 Sankyo Co Azasteroid compounds for the treatment of prostatic hypertrophy their preparation and use
US5304562A (en) * 1991-10-09 1994-04-19 Ciba-Geigy Corporation 17β-substituted Aza-androstane derivatives

Also Published As

Publication number Publication date
HU9203189D0 (en) 1992-12-28
NZ244640A (en) 1994-12-22
NO923911D0 (no) 1992-10-08
AU657579B2 (en) 1995-03-16
CA2080054A1 (en) 1993-04-10
EP0538192A1 (de) 1993-04-21
HUT62600A (en) 1993-05-28
ES2101073T3 (es) 1997-07-01
JPH05213989A (ja) 1993-08-24
US5378710A (en) 1995-01-03
US5304562A (en) 1994-04-19
ZA927747B (en) 1993-04-13
FI924529A0 (fi) 1992-10-07
IL103361A0 (en) 1993-03-15
IL103361A (en) 1997-06-10
MX9205792A (es) 1993-08-01
EP0538192B1 (de) 1997-04-23
ATE152121T1 (de) 1997-05-15
DE59208383D1 (de) 1997-05-28
FI924529A7 (fi) 1993-04-10
KR930007969A (ko) 1993-05-20
GR3024013T3 (en) 1997-10-31
DK0538192T3 (da) 1997-05-20
TW263513B (enExample) 1995-11-21
AU2626192A (en) 1993-04-22

Similar Documents

Publication Publication Date Title
NO923911L (no) Nye 17beta-substituerte aza-androstan derivater
ES2170252T3 (es) Tetrahidroimidazopiridoindoldionas como inhibidores de cgmp especifico pde.
SE8503680D0 (sv) Indolderivat
DK57492A (da) Farmaceutiske praeparater af n-phenylbenzamidderivater
NO162467C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive imidazo (1,5)-pyridiner og deres dihydro- og tetrahydroderivater.
SE8800949D0 (sv) Aromatiska karboxylsyraderivat och anvendning av dessa som mellanprodukter for framstellning av aromatiska heterocykliska derivat med terapeutiska och kosmetiska egenskaper
CY1111265T1 (el) Χρηση πεπτιδικων παραγωγων για διεγερση διαφοροποιησης κυτταρου
ES2057126T3 (es) Metodo de tratamiento de la caquexia y algunos nuevos compuestos para utilizar en este metodo.
NZ301645A (en) (R)-(-)-methyl phenyl oxazolidinone derivatives, pharmaceutical preparations and use for treating TNF stimulated diseases
CU22960A3 (es) Tienilazolilalcoxietanaminas, su preparación y su aplicación como medicamentos
MX9804052A (es) Compuestos de mercaptoalquilpeptidilo que tienen un substituyente de imidazol y su uso como inhibidores de metaloproteinasas (mmp) y/o factor de necrosis tumoral (tnf).
DK0526313T3 (da) Nye ureaderivater, deres fremstilling og terapeutiske anvendelse
ES2008735A6 (es) Procedimiento de prpeparacion de una composicion para inducir y estimular el crecimiento de los cabellos y frenar su caida.
ATE74138T1 (de) Heptanoyl-glu-asp-ala-amino-saeureimmunstimulanten.
DE69419954D1 (de) Arzneimittel zur Behandlung von Hauterkrankungen
NO922151L (no) Gingerol og gingerdiolderivater som hypokolesterolemiske og antiatherosklerotiske midler
ATE16150T1 (de) Xanthinoxydasehemmer und verwendung von benztriazinderivaten.
NO893039D0 (no) Bruk av imidazopyrazol-derivater som analgesiske og antiinflammatoriske midler.
NO932002L (no) Nye tiosemikarbazonsyreestere
NO20082302L (no) Anvendelse av et pleuromutilinderivat innen vetrinaermedisin samt fremgangsmate for fremstilling av et medikament omfattende forbindelsen
EP0389178A3 (en) Acrylamido-penicillanic-acid derivatives